8-K: Microbot Medical Secures $29.2M, Eyes $63M More

Microbot Medical Inc. announced an inducement transaction raising $29.2 million from existing preferred investment option exercises, with potential for an additional $63 million from new Series J preferred investment options.

Summary

• Microbot Medical Inc. entered into an inducement agreement on September 14, 2025, with certain holders of existing preferred investment options (PIOs) to raise capital.
• Holders exercised existing Series F, G, H, and I PIOs to purchase an aggregate of 13,989,115 shares of common stock for cash.
• In consideration, Microbot Medical issued new Series J preferred investment options (New PIOs) to purchase up to an aggregate of 13,989,115 shares of common stock.
• The New PIOs have an exercise price of $4.50 per share, are exercisable six months after issuance, and expire two years thereafter.
• The first closing of the transaction occurred on September 16, 2025, generating approximately $25.2 million in gross proceeds from the exercise of 12,064,627 existing PIOs at prices ranging from $1.50 to $2.13 per share.
• A second closing is expected by October 15, 2025, to generate approximately $4.0 million in gross proceeds from the exercise of 1,924,488 existing PIOs at $2.10 per share.
• The total gross proceeds from the exercise of existing PIOs are expected to be approximately $29.2 million.
• If all New PIOs are fully exercised for cash, Microbot Medical could receive an additional approximately $63 million in gross proceeds.
• The net proceeds are intended for the continued development, commercialization, and regulatory activities for the LIBERTY Robotic System, potential acquisitions, IP portfolio expansion, and general corporate purposes.
• H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving a 7.0% cash fee, a 1.0% management fee, and various expense reimbursements, plus additional preferred investment options (Wainwright PIOs).
• An associated person of H.C. Wainwright & Co., LLC participated in the transaction, exercising 2,306,572 shares of Common Stock for $4,900,139.28 and receiving corresponding New PIOs.

Sentiment

Score: 6

Explanation: The capital raise provides essential funding for Microbot Medical's strategic initiatives and ongoing operations, which is a positive. However, the significant fees paid to the placement agent and the potential for future dilution from the new preferred investment options temper the overall positive sentiment, indicating a mixed financial impact.

Positives

• Secured approximately $29.2 million in gross proceeds from the exercise of existing preferred investment options, providing immediate capital.
• Potential to raise an additional approximately $63 million if the newly issued Series J preferred investment options are fully exercised, offering significant future funding capacity.
• Proceeds are earmarked for strategic initiatives including the development, commercialization, and regulatory activities of the LIBERTY Robotic System, as well as potential acquisitions and IP expansion.
• The transaction strengthens the company's balance sheet and provides working capital for ongoing operations.

Negatives

• Significant fees and compensation paid to the placement agent, H.C. Wainwright & Co., LLC, including an 8.0% cash fee on gross proceeds and additional preferred investment options.
• The issuance of new Series J preferred investment options, and the Wainwright PIOs, represents potential future dilution for existing shareholders if exercised.
• No assurance that the new Series J preferred investment options will be exercised, meaning the potential $63 million in additional proceeds is not guaranteed.
• The company has agreed to certain restrictions on issuing or announcing Common Stock or Common Stock Equivalents for 90 days and variable rate transactions for six months, limiting immediate financing flexibility.

Risks

• No assurance that the newly issued Series J preferred investment options will be exercised, which could impact future funding expectations.
• The company's need for and ability to obtain additional working capital to continue its transition to a commercially focused company.
• Market conditions could affect the exercise of preferred investment options and the company's ability to raise further capital.
• Inherent risks in the commercialization of the LIBERTY Endovascular Robotic System and the development of future versions or applications.
• Uncertainty in regulatory pathways and obtaining regulatory approvals for its medical devices.
• Uncertainty resulting from political, social, and geopolitical conditions, including potential changes at the FDA and disruptions from hostilities in the Middle East.
• Risks associated with the maintenance and enforcement of intellectual property rights.

Future Outlook

The company plans to utilize the net proceeds for the continued development, commercialization, and regulatory activities of its LIBERTY Robotic System. Additionally, funds are allocated for potential acquisitions of complementary assets or products, expansion and development of additional applications from its existing intellectual property portfolio, and for general working capital and corporate purposes. The company also expects to file a registration statement for the resale of the new PIO shares within 30 days and aims for it to be effective within 60-90 days.

Management Comments

• The company intends to use the net proceeds for the continued development, commercialization, and regulatory activities for the LIBERTY Robotic System.
• Management plans for potential acquisitions of complementary assets or products and the expansion and development of additional applications derived from the company's existing IP portfolio.
• Proceeds will also be used for working capital and other general corporate purposes.

Industry Context

This financing event occurs within the competitive medical device industry, specifically targeting the endovascular robotics segment. Microbot Medical's LIBERTY Robotic System aims to transform endovascular procedures by offering a single-use, remotely operated robotic solution focused on precision, efficiency, and provider safety. The capital raise is crucial for a development-stage company like Microbot to advance its technology, navigate regulatory pathways, and move towards commercialization in a sector that demands significant R&D investment and clinical validation.

Related Party Transactions

• H.C. Wainwright & Co., LLC served as the exclusive placement agent and received substantial compensation, including a 7.0% cash fee, a 1.0% management fee, and various expense reimbursements.
• H.C. Wainwright & Co., LLC or its designees were issued Wainwright PIOs as part of the compensation.
• An associated person of H.C. Wainwright & Co., LLC participated in the Inducement Transaction, exercising existing PIOs to purchase 2,306,572 shares of Common Stock for $4,900,139.28 and receiving corresponding New PIOs.

Stakeholder Impact

• Shareholders: Experience immediate dilution from the exercise of existing PIOs and face potential future dilution if the new Series J PIOs are exercised. However, the capital infusion supports company growth and strategic initiatives, potentially increasing long-term value.
• Employees: The capital raise provides funding for continued development and commercialization efforts, potentially ensuring job security and opportunities related to the LIBERTY Robotic System.
• Customers: The funding supports the continued development and commercialization of the LIBERTY Robotic System, potentially leading to improved products and wider availability.
• Creditors: The capital infusion improves the company's financial liquidity and stability, potentially reducing credit risk.
• Placement Agent (H.C. Wainwright & Co., LLC): Benefits significantly from substantial cash fees and the issuance of Wainwright PIOs, indicating a favorable transaction for the agent.

Next Steps

• Completion of the second closing of the inducement transaction by October 15, 2025.
• Filing of a registration statement on Form S-3 for the resale of the New PIO Shares within 30 calendar days.
• Efforts to have the Resale Registration Statement declared effective by the SEC within 60-90 calendar days.
• Continued development, commercialization, and regulatory activities for the LIBERTY Robotic System.
• Exploration of potential acquisitions of complementary assets or products.
• Expansion and development of additional applications derived from the company's existing IP portfolio.

Key Dates

Recommendation

The capital raise of $29.2 million, with a potential additional $63 million, provides crucial funding for Microbot Medical's LIBERTY Robotic System development and commercialization. This is a positive for a growth-stage medical device company. However, the transaction involves significant placement agent fees (8% cash plus warrants) and introduces substantial potential future dilution from the new Series J PIOs. While the funding is necessary, the terms and the inherent risks of commercializing a medical device, coupled with the dilutive structure, suggest a 'hold' recommendation. Investors should monitor the company's progress with the LIBERTY system, the exercise rate of the new PIOs, and the impact of future dilution before making further investment decisions.

Keywords

Microbot Medical, MBOT, Equity Financing, Preferred Investment Options, Capital Raise, LIBERTY Robotic System, Medical Device, Endovascular Robotics, H.C. Wainwright, SEC Filing, Form 8-K, Dilution